Mundipharma has once again received an industry award for its supply of prescription medicines.
Last night in Melbourne, Mundipharma was recognised when winning the Sigma “Specialised Ethical Supplier of the Year” Award. Other Nominees included Amgen and Novo Nordisk.
Robert Ingui, Finance and Operations director at Mundipharma said “These Awards are a wonderful acknowledgement of the extraordinary […]
Mundipharma ran its 100th Pain Management Master Classes in November 2015, with the program servicing over 4,500 healthcare practitioners all around Australia since it began.
The Pain Management Master Classes were launched in 2009 as part of the CARE by mundipharma® offering (Clinical Academic Resources & Education) which supplies healthcare practitioners with access to accredited education […]
Starting Friday 9 October, Mundipharma launched a month long cross media campaign on radio, newspapers and websites to prompt patients suffering constipation related to their pain medication to discuss the issue with their GP. The Sydney focused cross media campaign is a major initiative for Mundipharma and is being implemented after a pilot program successfully tested […]
Mundipharma Pty Limited launched their first Australian consumer campaign for Burnaid® in an effort to raise awareness of the brand and of how to treat burns adequately. Research* showed that 88% of burns happen at home, mostly in the kitchen, and people are using ice, butter or even toothpaste as treatments for their burns.
Mundipharma relaunched the www.burnaid.com.au website, including a […]
Purdue Pharma L.P. and AnaBios Corporation announced today the intent to form a joint venture aimed at accelerating the development of Purdue Pharma’s Nav1.7 sodium ion channel compounds for the treatment of chronic pain. The joint research and development effort would leverage Purdue Pharma’s intellectual property and lead compounds, combined with AnaBios’ Phase-X® technology.
Purdue Pharma […]
Purdue Pharma L.P. announced today the acquisition from VM Pharma LLC of VM-902A, a first-in-class, allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor, as well as the backup compounds and associated intellectual property for the potential treatment of chronic pain. TrkA is a member of a larger family of important signaling proteins known as tyrosine […]
Mundipharma rand Burnaid® recently made a significant donation to the Ravenshoe Café Explosion Response Fund created by the Julian Burton Burns Trust. The explosion at this Queensland café resulted in significant burn injuries in several people as well as two deaths. The Julian Burton Burns Trust organised for the collected funds to go directly to those […]
Mundipharma Laboratories GmbH and its independent associated company, Purdue Pharmaceuticals LP, today announced that they have entered into a global multi programme discovery and development collaboration with Laboratorios Esteve, S.A. to bring to market important next generation products for the management of pain. Under the agreements Mundipharma and Purdue could potentially make payments to Esteve […]
